“ While our mission remains the same to this day , we are now also focused on incorporating the latest science and technology into our processes as well as improving our research and development to tackle serious diseases across a variety of therapeutic areas . Over the last few decades , we have expanded into the pharmaceuticals sector , with the introduction of major drugs . A shift to biopharma occurred in 2009 , as we partnered with smaller companies , namely Medarex to bring forward new medicines to improve the quality of life of patients across the globe . At BMS , we have always prioritized innovation , whether by evolving to address the greatest patient needs or by adapting to the latest science and technology . This is one of the reasons why I love working here and helping to foster innovation within the supply chain ,” she adds .
Meeting patients ’ diverse needs
Imara delves into the range of products currently covered by BMS . “ We offer a broad selection of pharmaceutical drugs , including pills that come in bottles , blister packs , or tablets , as well as biologics that are typically administered as injectables , often in clinics and hospitals . More recently , we have expanded our portfolio into new modalities including cell and gene therapies . Cell therapy involves producing
42